Vir Biotechnology VIR 深 滬
等待開盤 12-12 09:30:00 美东时间
6.63
+0.080
+1.22%
華盛通- 最 高6.8289
- 今 開6.55
- 成交量 151.04万股
- 最 低 6.50
- 昨 收 6.55
- 總市值 9.22亿
- 52周最高 14.45
- 市盈率 靜 --
- 換手率 1.09%
- 52周最低 4.155
- 委 比 69.51%
- 總股本 1.39亿
- 歷史最高 141.01
- 量 比 0.71
- 振 幅 5.02%
- 歷史最低 4.155
- 每 手 1
- 風險率 1.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
Vir Biotechnology Completes Enrollment In ECLIPSE 1 Phase 3 Trial For Chronic Hepatitis Delta
– ECLIPSE 1 estimated date of last participant reaching primary endpoint (primary completion) in the fourth quarter of 2026, and topline data expected in the first quarter of 2027– ECLIPSE registrational program on
11-03 21:07
Medivir Postpones Nomination Committee Appointment Amid Rights Issue
Medivir AB ( ($SE:MVIR) ) has provided an announcement. Medivir AB has announce...
10-29 17:33
Theriva Biologics Addresses Unusual NYSE Trading Activity; Confirms No New Developments Since VIRAGE Trial Data Presentation At ESMO 2025
Theriva™ Biologics (NYSE:TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, announced today
10-25 02:35
生产经营｜广船国际自主研发双燃料客滚船命名交付
10月23日，由广船国际为全球领先的运输与物流企业MSC地中海航运集团旗下客渡轮运营商Grandi Navi Veloci（GNV）量身打造的一艘现代化大型绿色...
10-24 18:12
Medivir Licenses Remetinostat to Biossil for Global Development
Medivir AB ( ($SE:MVIR) ) just unveiled an update. Medivir AB has entered an ex...
10-23 15:03
LoanCare Enhances its Digital Retention Platform with New Features
Latest enhancements include Paid in Full Monitoring and RateTrak VIRGINIA BEACH, Va., Oct. 15, 2025 /PRNewswire/ -- LoanCare®, a leading national mortgage subservicer, today announced two ne...
10-15 21:30
生产经营｜提前263天 中船澄西交付2025年第20艘新造船
10月10日，中船澄西船舶修造有限公司为中信金融租赁有限公司建造的5号84500吨干散货船较合同期提前263天命名交付。 UPM公司高级副总裁Tomas Wi...
10-11 17:40
Vir Biotechnology Doses First Patient In Part 3 Of Its Phase 1 Trial Evaluating VIR-5500
– Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in combination with androgen receptor pathway inhibitors in first-line mCRPC– Clinical trial builds on
10-10 04:09
